Categories: News

PhotonPay Joins Circle’s Arc Public Testnet to Advance Global Payment Innovation

HONG KONG, Nov. 14, 2025 /PRNewswire/ — PhotonPay, an AI-powered financial infrastructure provider, has officially joined Circle’s Arc public testnet, an open, developer-friendly Layer-1 blockchain network designed to bring real-world economic activity onchain and evolve into the next-generation Economic Operating System (OS) for the internet.

- Advertisement -

Working alongside leading innovators in global payments, technology, and fintech, this initiative represents a major stride toward building open, programmable financial infrastructure. It also highlights a key shift in modernizing global payment systems and empowering enterprises to adopt blockchain-driven financial solutions.

- Advertisement -

Trusted by 200,000+ businesses worldwide to overcome banking and payment challenges, PhotonPay delivers simple, scalable, and customizable solutions – including accounts, card issuing, global payouts, online payment, FX management, and embedded finance.

- Advertisement -

Arc marks a significant milestone in developing open financial networks for the global economy. With predictable dollar-based fees, sub-second transaction finality, optional privacy configurations, and seamless integration into Circle’s full-stack platform, Arc supports diverse use cases across lending, capital markets, FX, and international payments.

- Advertisement -

Through its participation in Arc’s testnet, PhotonPay seeks to bridge traditional finance with blockchain-powered innovation, advancing transparency, security, and efficiency across the global financial ecosystem.

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/photonpay-joins-circles-arc-public-testnet-to-advance-global-payment-innovation-302615689.html

- Advertisement -

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

2 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

2 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

2 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

2 hours ago